Bibliography

Back to Publications
    1. O’Connor CM, Psotka MA, Fiuzat M, et al. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018;71(4):443-453. doi:10.1016/j.jacc.2017.11.048.
    2. O’Connor CM, Bristow MR. Changing the Research Culture in the United States. JACC Heart Fail. 2018;6(4):344-345. doi:10.1016/j.jchf.2018.03.001.
    3. Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. JAMA Cardiol. 2018;3(10):1011-1019. doi:10.1001/jamacardio.2018.2559.
    4. Butler J, Packer M, Greene SJ, et al. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019;140(25):2108-2118. doi:10.1161/CIRCULATIONAHA.119.042155.
    5. Psotka MA, Fiuzat M, Carson PE, et al. Design of a “Lean” Case Report Form for Heart Failure Therapeutic Development. JACC Heart Fail. 2019;7(11):913-921. doi:10.1016/j.jchf.2019.07.001.
    6. Abraham WT, Psotka MA, Fiuzat M, et al. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. JACC Heart Fail. 2020;8(12):961-972. doi:10.1016/j.jchf.2020.10.002.
    7. Abraham WT, Fiuzat M, Psotka MA, O’Connor CM. Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19. JACC Heart Fail. 2020;8(5):423-425. doi:10.1016/j.jchf.2020.03.005.
    8. Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in Heart Failure Drug Development. JACC Heart Fail. 2020;8(6):429-440. doi:10.1016/j.jchf.2019.12.011.
    9. Psotka MA, Latta F, Cani D, et al. Publication Rates of Heart Failure Clinical Trials Remain Low. JACC. 2020;75(25):3151-3161. doi:10.1016/j.jacc.2020.04.068.
    10. O’Connor CM, Bristow MR. Changing U.S. Heart Failure Research Culture: Part 2—Recognizing Frontline Investigators and Coordinators. JACC Heart Fail. 2020;8(12):1050-1051. doi:10.1016/j.jchf.2020.10.010.
    11. Perego C, Sbolli M, Specchia C, et al. Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. JACC Heart Fail. 2020;8(12):973-983. doi:10.1016/j.jchf.2020.07.005.
    12. Psotka MA, Abraham WT, Fiuzat M, et al. Conduct of Clinical Trials in the Era of COVID-19. JACC. 2020;76(20):2368-2378. doi:10.1016/j.jacc.2020.09.544.
    13. Psotka MA, Fiuzat M, Solomon SD, et al. Challenges and Potential Improvements to Patient Access to Pharmaceuticals. Circulation. 2020;142(8):790-798. doi:10.1161/CIRCULATIONAHA.119.044976.
    14. Reza N, Tahhan AS, Mahmud N, et al. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circ Heart Fail. 2020;13(8):e006605. doi:10.1161/CIRCHEARTFAILURE.119.006605.
    15. Sinha SS, Psotka MA, Fiuzat M, et al. Barriers to Clinical Trial Efficiency and Patient Access: The Heart Failure Collaboratory Industry Survey. medRxiv. Preprint posted online June 29, 2020:2020.06.24.20124917. doi:10.1101/2020.06.24.20124917.
    16. Anchouche K, Elharram M, Oulousian E, et al. Use of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping Review. Can J Cardiol. 2021;37(9):1438-1449. doi:10.1016/j.cjca.2021.07.001.
    17. Bhatt AS, Abraham WT, Lindenfeld J, et al. Treatment of HF in an Era of Multiple Therapies. JACC Heart Fail. 2021;9(1):1-12. doi:10.1016/j.jchf.2020.10.014.
    18. Bhatt AS, Jering KS, Vaduganathan M, et al. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail. 2021;9(1):65-73. doi:10.1016/j.jchf.2020.11.003.
    19. DeFilippis EM, Fiuzat M. Putting the “Optimal” in Optimal Medical Therapy∗. JACC Heart Fail. 2021;9(1):39-41. doi:10.1016/j.jchf.2020.08.016.
    20. Lindenfeld J, Fiuzat M, O’Connor C. Promoting Diversity in Clinical Trial Leadership: A Call to Action. JACC Heart Fail. 2021;9(5):401-402. doi:10.1016/j.jchf.2021.03.005.
    21. Butt JH, Dewan P, DeFilippis EM, et al. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. JACC Heart Fail. 2022;10(8):543-555. doi:10.1016/j.jchf.2022.03.009.
    22. DeFilippis EM, Echols M, Adamson PB, et al. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. JAMA Cardiol. 2022;7(5):540-548. doi:10.1001/jamacardio.2022.0161.
    23. Fiuzat M, Hamo CE, Butler J, et al. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;79(5):504-510. doi:10.1016/j.jacc.2021.11.033.
    24. Lala A, O’Connor CM, Fiuzat M, Drazner MH, Mentz RJ. Recognizing Efforts that Support Clinical Trial Success: Site-Based Research Awards from the Heart Failure Collaboratory and Heart Failure Society of America. J Card Fail. 2022;28(9):1387-1389. doi:10.1016/j.cardfail.2022.08.001.
    25. Ostrominski JW, Hirji S, Bhatt AS, et al. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. JACC Heart Fail. 2022;10(1):1-11. doi:10.1016/j.jchf.2021.08.002.
    26. Psotka MA, Abraham WT, Fiuzat M, et al. Functional and Symptomatic Clinical Trial Endpoints. JACC Heart Fail. 2022;10(12):889-901. doi:10.1016/j.jchf.2022.09.012.
    27. Bhatt AS, Dimond M, Fiuzat M, et al. Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory. JACC Heart Fail. 2023;11(2):254-257. doi:10.1016/j.jchf.2022.11.024.
    28. Dimond MG, Fiuzat M, Mentz RJ, et al. Rewarding Site-Based Research. JACC Heart Fail. 2024;12(1):226-228. doi:10.1016/j.jchf.2023.07.032.
    29. Johansen ND, Vaduganathan M, Zahir D, et al. A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. Circ Heart Fail. 2023;16(2):e009729. doi:10.1161/CIRCHEARTFAILURE.122.009729
    30. Yehya A. Recognizing Physicians Beyond Revenue Value Units. J Card Fail. 2024;30(1):117-118. doi:10.1016/j.cardfail.2023.09.004. 
    31. Psotka MA. Step by Step. JACC Heart Fail. 2023;11(11):1531-1533. doi:10.1016/j.jchf.2023.06.016.
    32. Lala A, Hamo CE, Bozkurt B, et al. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies. JACC Heart Fail. 2024;12(1):1-15. doi:10.1016/j.jchf.2023.09.030.
    33. Blumer V, Bogaev RC, Fiuzat M. Sex Diversity in Heart Failure Clinical Trials. JACC Adv. 2024;3(1):100786. doi:10.1016/j.jacadv.2023.100786.
    34. Dimond MG, Ibrahim NE, Fiuzat M, et al. Left ventricular ejection fraction and the future of heart failure phenotyping. JACC Heart Fail. 2024;12(3):451-460. doi:10.1016/j.jchf.2023.11.005 
    35. Adamson PB, Echols M, DeFilippis EM, et al. Clinical trial inclusion and impact on early adoption of medical innovation in diverse populations. JACC Heart Fail. 2024;12(7):1212-1222. doi:10.1016/j.jchf.2024.02.015.
    36. Fleming TR, Wittes J, Fiuzat M, et al. Training the next generation of data monitoring committee members: an initiative of the Heart Failure Collaboratory. JACC Heart Fail. 2024;12(8):1317-1327. doi:10.1016/j.jchf.2024.02.016
    37. Bhatt AS, Fiuzat M. How did we score? Evaluating the utility of a score-based system for heart failure medical therapy. Circ Heart Fail. 2024;17(5):e011654. doi:10.1161/CIRCHEARTFAILURE.124.011654..
    38. Blumer V, Januzzi JL Jr, Lindenfeld J, et al. Heart failure drug development over the eras: from the Heart Failure Collaboratory. JACC Heart Fail. 2024;12(11):1803-1813. doi:10.1016/j.jchf.2024.03.021
    39. Rao VN, Hellkamp AS, Thomas LE, et al. Optimal medical therapy and outcomes among patients with chronic heart failure with reduced ejection fraction. JACC Heart Fail. 2024;12(11):1862-1875. doi:10.1016/j.jchf.2024.05.026.
    40. Bhatt AS, Chatur S, Claggett BL, et al. Gamified behavioral science intervention to enhance trial enrollment. JACC Heart Fail. 2024;12(11):1939-1941.
    41. Reza N, Fiuzat M, Konstam MA. Measures to improve trial enrollment: it’s game time! JACC Heart Fail. 2024;12(11):1942-1945. doi:10.1016/j.jchf.2024.08.006.
    42. Cunningham JW, Abraham WT, Bhatt AS, et al. Artificial intelligence in cardiovascular clinical trials. J Am Coll Cardiol. 2024;84(20):2051-2062. doi:10.1016/j.jacc.2024.08.069.
    43. Evans Y, Fiuzat M, Jessup M, et al. Rewarding site-based research: the unsung heroes of heart failure clinical research. Circ Heart Fail. 2024;17(11):e012481. doi:10.1161/CIRCHEARTFAILURE.124.012481.
    44. Shalowitz EL, Jhund PS, Psotka MA, et al. Where’s the remote? Failure to report clinical workflows in heart failure remote monitoring studies. J Card Fail. 2025;31(9):1420-1429
    45. Lala A, Coca S, Feinman J, et al. Standardized definitions of changes in kidney function in trials of heart failure: JACC Expert Panel from the HF-ARC. J Am Coll Cardiol. 2025;85(7):766-781. doi:10.1016/j.jacc.2024.11.041.
    46. Fiuzat M, Ferlin K, Gottschalk L, et al. An innovative program for evidence generation: HFC perspective on the FDA Total Product Life Cycle Advisory Program. JACC Heart Fail. 2025;13(4):647-650. doi:10.1016/j.jchf.2025.01.011.
    47. Cavagna I, Fiuzat M, Lala A, et al. Inertia is not an option: laying the foundation for a consensus on the assessment of kidney function in acute decompensated heart failure. J Card Fail. 2025;31(6):953-956.
    48. Cunningham JW, O’Connor CM. The future of artificial intelligence–assisted event adjudication. JACC Heart Fail. 2025;13(5):722-724. doi:10.1016/j.jchf.2025.03.015.
    49. Butler J, Usman MS, Gandotra C, et al. Patient-reported outcomes as end points in heart failure trials. Circulation. 2025;151(15):1111-1125. doi:10.1161/CIRCULATIONAHA.124.072158.
    50. Mann DL, Felker GM, Unger EF, et al. Derisking phase II clinical trials in heart failure: a position paper from JACC: Basic to Translational Science and the Heart Failure Collaboratory. JACC Basic Transl Sci. 2025;10(5):677-688. doi:10.1016/j.jacbts.2025.04.003.
    51. Leifer ES, Troendle JF, Psotka MA, Sachdev V. Hierarchical analysis of composite time-to-event end points in heart failure clinical trials using time in clinical state. Circ Heart Fail. 2025;18(7). doi:10.1161/CIRCHEARTFAILURE.124.011783.
    52. DeFilippis EM, Blumer V, Makuvire TT, et al. Social drivers of health in heart failure trials: an analysis from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(9):102546. doi:10.1016/j.jchf.2025.102546.
    53. Fiuzat M, Butler J, Stockbridge N, et al. Background therapy for HF clinical trials: a randomized crossover debate from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(10):102596. doi:10.1016/j.jchf.2025.102596.
    54. Armbruster S, McCaw ZR, Jering K, et al. Capturing totality of treatment effects: a model-free approach to analyzing multiple event-time data from heart failure studies. JACC Heart Fail. 2025;13(10):102605. doi:10.1016/j.jchf.2025.102605.
    55. Blumer V, Lindenfeld J, Lala A, et al. Let us call it cardiogenic preshock: a working definition from the Heart Failure Collaboratory. J Am Coll Cardiol. 2025;86(11):832-835. doi:10.1016/j.jacc.2025.07.017.
    56. Bhatt AS, De Oliveira-Gomes D, Fiuzat M, et al. Assessing medical therapy optimization in cardiovascular-kidney-metabolic clinical trials: an initiative from the Heart Failure Collaboratory. JACC Heart Fail. 2026;14(3):102727. doi:10.1016/j.jchf.2025.102727.
    57. Rivera AD, Fiuzat M, Bristow MR, et al. Backbone of trials in a challenging environment: recognizing site-based research teams. Circ Heart Fail. 2025;18(11):e013821. doi:10.1161/CIRCHEARTFAILURE.125.013821.
    58. Gupta M, Fiuzat M, Dimond M, et al. Promoting representation in heart failure clinical trials: recommendations from the Heart Failure Collaboratory. JACC Heart Fail. 2025;13(7):102485. doi:10.1016/j.jchf.2025.03.033.
    59. Kose O, Sahal A, Zhang GK, et al. Framework for analytical validation of DHT-based actigraphy and signal measures in HF trials: the VALIDATE-HF program. JACC Heart Fail. 2026;14(4):102831. doi:10.1016/j.jchf.2025.102831.
    60. Blumer V, Bozkurt B, Konstam MA, et al. Subgroups and special populations in heart failure clinical trials: insights from the HFC-ARC Expert Consensus Panel. JACC Heart Fail. 2026;14(4):102775. doi:10.1016/j.jchf.2025.102775.
    61. Shalowitz EL, Jhund PS, Psotka MA, et al. Standardized reporting in heart failure noninvasive remote monitoring trials: interventions to catalyze data into action. JACC Heart Fail. 2026;14(5):102849. doi:10.1016/j.jchf.2025.102849.
    62. Krantz MJ, Senatore F, Psotka MA, et al. Heart failure endpoints in Food and Drug Administration pivotal trials. Eur Heart J. 2026;47(19):2245-2254. doi:10.1093/eurheartj/ehag069
    63. Fiuzat M, O’Connor CM, Mann DL. In memoriam: Michael R. Bristow, MD, PhD. J Card Fail. 2026;32(3):688-690. doi:10.1016/j.cardfail.2026.01.003.
    64. McCallum W, Tighiouart H, Tuttle M, et al. Association of the timing of acute declines in kidney function in acute heart failure with cardiovascular and kidney outcomes. Am J Kidney Dis. 2026;87(6):808-819.e1. doi:10.1053/j.ajkd.2025.12.005.
    65. Batchelor WB, Califf R, Mehran R, et al. Aligning coronary stent trial enrollment with the U.S. intended-use population: implications of site selection. J Am Coll Cardiol. 2026;87(16):2163-2176. doi:10.1016/j.jacc.2026.01.088.
    66. Pan T, Tian L, Claggett B, et al. Bayesian counterparts to the frequentist Kaplan-Meier estimate and its summary measures for comparative heart failure clinical studies. J Card Fail. 2026;32(7):1238-1245. doi:10.1016/j.cardfail.2026.02.046.
    67. Rivera AD, Psotka MA, Fiuzat M, O’Connor CM; Heart Failure Collaboratory. Forty years of heart failure drug clinical trials: have we made progress on enrollment? JACC Heart Fail. 2026;14(8):103068. doi:10.1016/j.jchf.2026.103068.
    68. Echols MR, Fiuzat M, Brinkley DM, et al. Rebuilding U.S. heart failure site-based research: a national expert authority blueprint from the Heart Failure Collaboratory. JACC Heart Fail. Published online June 17, 2026. doi:10.1016/j.jchf.2026.103165.
    69. Blumer V, Wittes JT, Pomeroy JE, et al. Select contemporary statistical concepts in heart failure clinical trials: insights from the Heart Failure Collaboratory. JACC Heart Fail. Published online June 26, 2026. doi:10.1016/j.jchf.2026.103180.
    70. Makker S, Badrouchi S, Xu D, et al. Clinical trial source document verification using a large language model. JACC Adv. 2026;5(9):103108. doi:10.1016/j.jacadv.2026.103108
    71. Guilliod CR, Blumer V, De Oliveira-Gomes D, et al. Demographic enrollment by region in heart failure trials: insights from GUIDE-IT and HF-ACTION. J Card Fail. Published online July 16, 2026. doi:10.1016/j.cardfail.2026.07.004
    72. Hamilton S, Fiuzat M, Starling RC, et al. The impact of artificial intelligence-enabled tools on electronic health record-based evidence generation in heart failure. JACC Heart Fail. Published online September 15, 2026. doi:10.1016/j.jchf.2026.103354.
    73. Paydarfar D, Claggett BL, Tian L, et al. Bayesian survival analysis for heart failure clinical trials in the presence of competing risks. JACC Heart Fail. Published online October 26, 2026. doi:10.1016/j.jchf.2026.103474.